Entity

Time filter

Source Type


Feher L.Z.,Hungarian Academy of Sciences | Pocsay G.,Pandy Kalman County Hospital | Krenacs L.,Laboratory of Tumour Pathology and Molecular Diagnostics | Zvara A.,Hungarian Academy of Sciences | And 7 more authors.
Pathology and Oncology Research | Year: 2012

Papillary thyroid carcinoma (PTC) is the most common well-differentiated thyroid cancer. Although the great majority of the cases exhibit an indolent clinical course, some of them develop local invasion with distant metastasis, and a few cases transform into undifferentiated/anaplastic thyroid carcinoma with a rapidly lethal course. To identify gene copy number alterations predictive of metastatic potential or aggressive transformation, arraybased comparative genomic hybridization (CGH-array) was performed in 43 PTC cases. Formalin-fixed and paraffinembedded samples from primary tumours of 16 cases without metastasis, 14 cases with only regional lymph node metastasis, and 13 cases with distant metastasis, recurrence or extrathyroid extension were analysed. The CGH-array and confirmatory quantitative real-time PCR results identified the deletion of the EIF4EBP3 and TRAK2 gene loci, while amplification of thymosin beta 10 (TB10) and Tre-2 oncogene regions were observed as general markers for PTC. Although there have been several studies implicating TB10 as a specific marker based on gene expression data, our study is the first to report on genomic amplification. Although no significant difference could be detected between the good and bad prognosis cases in the A-kinase anchor protein 13 (AKAP13) gene region, it was discriminative markers for metastasis. Amplification in the AKAP13 region was demonstrated in 42.9% and 15.4% of the cases with local or with distant metastasis, respectively, while no amplification was detected in nonmetastatic cases. AKAP13 and TB10 regions may represent potential new genomic markers for PTC and cancer progression. © Arányi Lajos Foundation 2011. Source


Kemeny L.,Hungarian Academy of Sciences | Kemeny L.,University of Szeged | Csoma Z.,University of Szeged | Bagdi E.,Laboratory of Tumour Pathology and Molecular Diagnostics | And 5 more authors.
British Journal of Dermatology | Year: 2010

Background One of the major technological breakthroughs in the last decade is represented by the diversified medical applications of light-emitting diodes (LEDs). LEDs emitting in the ultraviolet (UV) B spectrum might serve as a more convenient alternative for targeted delivery of phototherapy in inflammatory skin diseases such as psoriasis. Objectives We investigated the efficacy and safety of a new UVB-LED phototherapeutic device in chronic plaque-type psoriasis. Methods Twenty patients with stable plaque-type psoriasis were enrolled into a prospective, right-left comparative, open study. Symmetrical lesions located on extremities or trunk were chosen; one lesion was treated with the study device, whereas the other lesion served as an untreated control. Two treatment regimens were used in the study, one with an aggressive dose escalation similar to those used for outpatient treatment and one with slow increase in dose, similar to those used for treatment at home. Results Patients in both groups responded rapidly to the UVB-LED therapy. Early disease resolution was observed in 11 patients (seven in the first group and four in the second group). Overall improvement at end of therapy was 93% in the high-dose group and 84% in the low-dose group. Four patients from the high-dose group and five from the low-dose group were still in remission at the 6-month follow-up visit. Conclusions These results suggest that this innovative UVB-LED device is effective in the treatment of localized psoriasis and may be useful in other UV-responsive skin diseases. © 2010 British Association of Dermatologists. Source


Marton I.,University of Szeged | Krenacs L.,Laboratory of Tumour Pathology and Molecular Diagnostics | Bagdi E.,Laboratory of Tumour Pathology and Molecular Diagnostics | Bakos A.,Laboratory of Tumour Pathology and Molecular Diagnostics | And 2 more authors.
Pathology and Oncology Research | Year: 2015

Systemic mastocytosis (SM) is a rare chronic myeloproliferative neoplasm with only limited epidemiologic data published so far. We aimed to analyze the clinical and molecular diagnostic features, and the prognosis and cumulative incidence of SM cases in a cohort of south-eastern Hungarian patients of 13 year follow up. In the period 2001–2013, 35 consecutive SM cases were diagnosed in our regional centre. Immunophenotype, KIT D816V mutation frequency and clinical characteristics, and the prognosis impact of clinical subtypes were tested and compared with published data. Indolent SM (ISM) was diagnosed in 14 patients, SM with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in 15 patients and aggressive SM (ASM) in 6 patients. The KIT D816V mutation was found in 11/14 (78 %) of the ISM cases, in 12/15 (80 %) of the SM-AHNMD cases and in 5/6 (83 %) of the ASM cases. The life expectancy of ISM patients was better, whereas the SM-AHNMD and ASM groups exhibited a reduced median survival. The cumulative incidence for 13 year of the SM was 0.27/10,000. We detected lower 13 year cumulative SM incidence than of published epidemiologic data due to in our analyses involved only those patients who had bone marrow biopsy and histopathologically confirmed SM. This clinical overview clearly showed that the clinical characteristics differ between ISM (UP, anaphylaxis and osteoporosis) and SM-AHNMD/ASM (cytopenia, eosinophilia and splenomegaly). © 2015 Arányi Lajos Foundation Source

Discover hidden collaborations